Phil Graham

SVP, Chief Development Officer

Professional Overview
Phil Graham is an accomplished pharmaceutical industry executive with extensive experience in product development, program management, and strategic leadership. As the SVP and Chief Development Officer at Avilar Therapeutics, he oversees the company's clinical pipeline and guides the development of innovative therapeutics. With a strong technical background and a proven track record of driving successful programs, Graham is a respected leader in the field of pharmaceutical R&D.

Experience Summary

Current Role
As the SVP and Chief Development Officer at Avilar Therapeutics since 2021, Graham is responsible for leading the company's development efforts, including clinical trial design, regulatory strategy, and cross-functional project management. Under his leadership, Avilar has advanced multiple investigational compounds into late-stage clinical trials, demonstrating the company's commitment to bringing transformative treatments to patients.

Career Progression
Prior to his current role, Graham served as the SVP and Chief Development Officer at Sojournix, Inc., where he was instrumental in advancing the company's pipeline and securing regulatory approvals. He has also held various leadership positions at Concert Pharmaceuticals and EPIX Pharmaceuticals, where he gained extensive experience in product development, program management, and strategic planning.

Throughout his career, Graham has demonstrated a strong ability to navigate complex regulatory environments, build high-performing teams, and deliver tangible results. His contributions have had a significant impact on the advancement of novel therapies and the growth of the companies he has been associated with.

Academic Background
Graham holds a Ph.D. in Pharmaceutical Sciences from the University of Massachusetts Amherst, where he specialized in drug delivery and formulation development. His academic achievements, combined with his industry expertise, have positioned him as a respected thought leader in the pharmaceutical research and development landscape.

Areas of Expertise

• Pharmaceutical product development and clinical trial strategy

• Regulatory affairs and interactions with global health authorities

• Cross-functional team leadership and project management

• Translational research and early-stage drug discovery

• Strategic planning and business development

Professional Impact
During his tenure at Sojournix, Inc., Graham successfully led the development and regulatory approval of a novel small-molecule therapeutic for the treatment of a rare endocrine disorder. This achievement not only provided patients with a much-needed treatment option but also garnered significant industry recognition for the company.

As a development advisor at Reveal Pharmaceuticals, Graham has leveraged his extensive expertise to guide the company's strategic decision-making and contribute to the advancement of their pipeline. His industry insights and collaborative approach have been invaluable in driving Reveal's innovation efforts.

Conclusion
With his deep technical expertise, proven leadership abilities, and a demonstrated commitment to delivering transformative treatments, Phil Graham is well-positioned to continue driving the development of innovative therapeutics at Avilar Therapeutics. His extensive experience and track record of success make him a valuable asset in the pharmaceutical industry, as he continues to advance the field and positively impact patient lives.